Results 181 to 190 of about 53,685 (285)

Ekbom Spectrum Psychosis Associated with 24-hour Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion in Parkinson's Disease. [PDF]

Clin Psychopharmacol Neurosci
Meloni M, Ascaniis F, Orofino G, Marano M, Mulas M, Puligheddu M, Mascia MM.   +6 more
europepmc   +1 more source

Remote Versus In‐Person Follow‐up Programming After Subthalamic Deep Brain Stimulation for Parkinson's Disease: A Multicenter Randomized Noninferiority Trial

Movement Disorders, EarlyView.
Abstract Background Remote programming of deep brain stimulation may improve access to specialized postoperative care for people with Parkinson's disease, but prospective randomized evidence remains limited. Objective We aimed to determine whether remote follow‐up programming after standardized inpatient initiation is noninferior to conventional in ...
Juhi Shaik, Weidong Zhang, Verena Zentsch, Carsten Buhmann, Ute Hidding, Thomas M. Kinfe, Martin Regensburger, Jost‐Julian Rumpf, Alfons Schnitzler, Jing Dong, Maximilian Scherer, Elisabeth Kaufmann, Johannes Levin, Alexander Crispin, Günter Höglinger, Jan H. Mehrkens, Thomas Koeglsperger   +16 more
wiley   +1 more source

Long-term safety profile of opicapone in patients with Parkinson's disease and early fluctuations. [PDF]

Front Neurol
Ferreira JJ, Stocchi F, Antonini A, Rascol O, Pavese N, Ebersbach G, Kulisevsky J, Höglinger G, Ramos D, Rocha JF, Brigas HC, Holenz J, Poewe W.   +12 more
europepmc   +1 more source

Cortical Cholinergic Pathway Degeneration Reflects Cognitive Impairment and Dementia in Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background Cognitive impairment is a prevalent and debilitating feature of Parkinson's disease (PD). Increasing evidence from postmortem and in vivo positron emission tomography imaging studies supports cholinergic dysfunction in PD. There is, however, little evidence regarding the influence of the structural integrity of cortical cholinergic ...
Nicola M. Slater, Daniel J. Myall, Reza Shoorangiz, Wassilios G. Meissner, Ian J. Kirk, Ross J. Keenan, Rebecca M. Lee, Kyla‐Louise Horne, Michael R. MacAskill, Campbell J. Le Heron, Toni L. Pitcher, Tim J. Anderson, Tracy R. Melzer, John C. Dalrymple‐Alford   +13 more
wiley   +1 more source

Real-World Use of Opicapone in Management of Patients with Parkinson's Disease and Early Motor Fluctuations in Spain: 12-Month Interim Analysis of REONPARK Study. [PDF]

Brain Sci
López-Manzanares L, Cerdán Sánchez M, Solano Vila B, Delgado Ballestero T, García-Ramos R, García Caldentey J, Rodríguez-Sanz A, Olivares Romero J, Gaston I, Carmona-Abellán M, Mata Álvarez-Santullano M, Vázquez Picón R, Rodríguez-De Miguel M, Tegel Ayuela I, Magalhães D, Holenz J, On Behalf Of The Reonpark Study Group.   +16 more
europepmc   +1 more source

Cross‐Cohort Evidence Links KCNJ6 rs702859 to Impulsive–Compulsive Phenotypes in Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background Impulse control disorders (ICDs) and related compulsive behaviors (CBs) are frequent non‐motor complications of Parkinson's disease (PD) with a probable genetic contribution. Objective To investigate whether genetic variants involved in reward and punishment processing are associated with impulsive–compulsive phenotypes in PD ...
Sergio García‐Díaz, Juan Francisco Martín‐Rodríguez, Laura Muñoz‐Delgado, Rafael Díaz‐Belloso, Silvia Jesús, María Teresa Periñán, Miguel Martín‐Bórnez, Ana M. Castellano‐Guerrero, Elena Ojeda‐Lepe, Daniel Macías‐García, Astrid Adarmes‐Gómez, Dolores Buiza‐Rueda, Marta Bonilla‐Toribio, Elena Iglesias‐Camacho, Manuela San‐Eufrasio, Cristina Pérez‐Calvo, Rocío Pineda‐Sánchez, Francisco Javier Gómez‐Campos, Antonio Luque‐Ambrosiani, Fátima Carrillo‐García, Pilar Gómez‐Garre, Pablo Mir   +21 more
wiley   +1 more source

Neuromelanin‐Sensitive MRI as a Marker of Clinical Severity and Disease Burden in Parkinson's Disease: A Systematic Review and Meta‐analysis

Movement Disorders, EarlyView.
Abstract The neuropathology of Parkinson's disease (PD) is characterized in part by the degeneration of catecholaminergic neurons, particularly dopaminergic neurons in the substantia nigra pars compacta (SNpc) and noradrenergic neurons in the locus coeruleus (LC), yet no validated in vivo biomarker quantifies this process.
Rayo Akande, Thomas Kustermann, Štefan Holiga, Judith Anzures‐Cabrera, Patrik Brundin, Gennaro Pagano   +5 more
wiley   +1 more source

Long-Term Clinical Efficacy, Safety, and Polypharmacy Simplification of Levodopa-Entacapone-Carbidopa Intestinal Gel in Advanced Parkinson's Disease: An 18-Month Longitudinal Study. [PDF]

J Clin Med
Orbán-Kis K, Szatmári S, Constantin VA, Szász RM, Bățagă S, Szederjesi J, Ciorba M, Nagy EE, Neagoe RM, Kelemen K, Bíró K, Ciorba Nicoleta C, Mihály I, Frigy A, Szász JA.   +14 more
europepmc   +1 more source

Therapeutic Impact of GLP‐1 Receptor Agonists on Parkinson's Disease: A Scoping Review

Neurology and Clinical Neuroscience, EarlyView.
ABSTRACT No disease‐modifying treatment exists for Parkinson's disease (PD). Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have gained attention as promising candidates for neuroprotection, given documented expression of GLP‐1 receptors within the central nervous system and the contribution of brain insulin resistance to dopaminergic ...
João Pedro Henriques, João Pedro Stringhetta Rahal, Rafael da Cunha Gomes Ribeiro, Enzo Bogucheski Ribeiro Machado, Carlos Antonio Negrato   +4 more
wiley   +1 more source

Continuous Subcutaneous Foslevodopa/Foscarbidopa Improves Nonmotor Symptoms and Fluctuations in Parkinson's Disease. [PDF]

Eur J Neurol
De Micco R, Ciaramaglia O, Siciliano M, Sant'Elia V, Cabato C, Ambrosio F, Tessitore A.   +6 more
europepmc   +1 more source